Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): A prospective, international, randomised, placebo-controlled trial

The Lancet Infectious Diseases

Volumn 14, Issue 7, 2014, Pages 563-571

  Mfinanga, Sayoki G ^a   Kirenga, Bruce J ^b   Chanda, Duncan M ^c   Mutayoba, Beatrice ^a   Mthiyane, Thuli ^d   Yimer, Getnet ^e   Ezechi, Oliver ^f   Connolly, Cathy ^d   Kapotwe, Vincent ^c   Muwonge, Catherine ^g   Massaga, Julius ^a   Sinkala, Edford ^c   Kohi, Wanze ^a   Lyantumba, Lucinda ^k   Nyakoojo, Grace ^j   Luwaga, Henry ^j   Doulla, Basra ^h   Mzyece, Judith ^c   Kapata, Nathan ^k   Vahedi, Mahnaz ^l   Mwaba, Peter ^c,k   Egwaga, Saidi ⁱ   Adatu, Francis ^j   Pym, Alex ^d   Joloba, Moses ^k   Rustomjee, Roxana ^d   Zumla, Alimuddin ^c,m,n   Onyebujoh, Philip ^o   more..

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c UNIVERSITY TEACHING HOSPITAL   (Zambia)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^e ADDIS ABABA UNIVERSITY   (Ethiopia)

^f NIGERIAN INSTITUTE OF MEDICAL RESEARCH   (Nigeria)

^g WHO TDR TB HAART Project   (Uganda)

^h MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

ⁱ MINISTRY OF HEALTH AND SOCIAL WELFARE   (Tanzania)

^j MINISTRY OF HEALTH   (Uganda)

^k MINISTRY OF HEALTH   (Zambia)

^l WORLD HEALTH ORGANIZATION   (Switzerland)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^o WHO Regional Office for Africa   (Zimbabwe)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; PLACEBO; ZIDOVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTENTION TO TREAT ANALYSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; SOUTH AFRICA; TANZANIA; TREATMENT FAILURE; UGANDA; ZAMBIA; ANEMIA; BACTERIUM CULTURE; CARDIOVASCULAR DISEASE; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; EYE DISEASE; GASTROINTESTINAL DISEASE; INTERMETHOD COMPARISON; KAPOSI SARCOMA; LIVER DYSFUNCTION; MORTALITY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; RESPIRATORY TRACT DISEASE; SKIN DISEASE; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; PROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY;

EID: 84904766772     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70733-9     Document Type: Article

References (30)

1. World Health Organisation Global Tuberculosis report 2013 (accessed Nov 12, 2013). http://www.who.int/tb/publications/global_report/en/.
2. Lawn SD, Kranzer K, Wood R Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 2009, 30:685-699.
3. Lawn SD, Torok ME, Wood R Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 2011, 24:34-42.
4. Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009, 20:339-345.
5. McIlleron H, Meintjes G, Burman WJ, Maartens G Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007, 15:S63-S75.
6. French MA, Price P, Stone SF Immune restoration disease after antiretroviral therapy. AIDS 2004, 18:1615-1627.
7. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012, 157:313-324.
8. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706.
9. Tabarsi P, Saber-Tehrani AS, Baghaei P, et al. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc 2009, 12:1758-2652.
10. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007, 13:1001-1007.
11. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009, 50:148-152.
12. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders (accessed Feb 2, 2014). http://www.who.int/tb/publications/2012/tb_hiv_policy_9789241503006/en/.
13. Division of AIDS table for grading the severity of adult and pediatric adverse events version 1.0 (accessed Feb 10, 2014). http://rsc.tech-res.com/document/safetyandpharmacovigilance/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf.
14. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523.
15. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011, 365:1492-1501.
16. Blanc F-X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481.
17. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011, 365:1482-1491.
18. Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr 2012, 60:377-383.
19. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011, 52:1374-1383.
20. Soeters HM, Poole C, Patel MR, Van Rie A The effect of tuberculosis treatment at combination antiretroviral therapy initiation on subsequent mortality: a systematic review and meta-analysis. PLoS One 2013, 8:0078073.
21. Sileshi B, Deyessa N, Girma B, Melese M, Suarez P Predictors of mortality among TB-HIV co-infected patients being treated for tuberculosis in corthwest Ethiopia: a retrospective cohort study. BMC Infect Dis 2013, 13:297.
22. Worodria W, Massinga-Loembe M, Mazakpwe D, et al. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr 2011, 58:32-37.
23. Kirenga BJ, Levin J, Ayakaka I, et al. Treatment outcomes of new tuberculosis patients hospitalized in kampala, uganda: a prospective cohort study. PLoS One 2014, 9:e90614.
24. Ziske J, Kunz A, Sewangi J, et al. Hematological changes in women and infants exposed to an AZT-containing regimen for prevention of mother-to-child-transmission of HIV in Tanzania. PLoS One 2013, 8:6.
25. Moyle G, Sawyer W, Law M, Amin J, Hill A Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther 2004, 26:92-97.
26. Shelburne SA, Montes M, Hamill RJ Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006, 57:167-170.
27. Ullrich A, Ott JJ, Vitoria M, Martin-Moreno JM, Atun R Long-term care of AIDS and non-communicable diseases. Lancet 2011, 377:639-640.
28. Remais JV, Zeng G, Li G, Tian L, Engelgau MM Convergence of non-communicable and infectious diseases in low- and middle-income countries. Int J Epidemiol 2013, 42:221-227.
29. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009, 360:1815-1826.
30. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824.